Clinical Trials Browser

Phase 1/2 × disitamab vedotin × 90 days × Clear all

NCT06966453 2026-03-04

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

Phase 1/2 Recruiting

Breast Neoplasms